Medicare drug plans are increasingly excluding coverage of new specialty drugs that treat complex conditions like cancers and autoimmune diseases. New research from the USC Schaeffer Center shows how ...

Telling yourself you're doing the best with what you have is one of many examples of compassionate self-care, writes ...

This study demonstrated progressive CP enlargement over time in individuals with RRMS, averaging 1.4% a year with significant variation per participant. CP enlargement correlated with the expansion of ...

Please provide your email address to receive an email when new articles are posted on . Individuals enrolled in the open-label extension experienced low discontinuation rates. Those who remained in ...

Conference MDAngle offers personal perspectives from conference attendees, showcasing their anticipation, quick takeaways, and insights into how the presented research will impact their patients. Dr ...

Frexalimab, an investigational second-generation CD40 ligand (CD40L) inhibitor, led to fewer new gadolinium-enhancing T1-weighted lesions in relapsing multiple sclerosis (MS), a phase II trial showed.

Rituximab may be an attractive treatment option for patients with relapsing-remitting multiple sclerosis (MS), suggest phase II study findings showing its efficacy in controlling inflammatory activity ...

Kesimpta is a medicine used to treat relapsing forms of multiple sclerosis (MS). Relapsing forms of MS include clinically isolated syndrome, relapsing-remitting MS, and active secondary progressive MS ...

NICE has backed NHS use of natalizumab, a key treatment option that is safe for use in pregnancy, for more patients with multiple sclerosis. NICE has said Biogen's Tysabri can now be used by the NHS ...

Good physical performance is associated with better cognition in people with relapsing-remitting MS, according to a recent study by the University of Eastern Finland. Good functional capacity was also ...